• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events.
CONCLUSION:: In our study population, patients treated with intravitreal bevacizumab were significantly more likely to experience stroke during 2 years after first injection. PMID: 30618282 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - January 8, 2019 Category: Opthalmology Authors: Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J Tags: Eur J Ophthalmol Source Type: research

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration
We thank Drs Hanhart and Vinker for their interest in our study. The authors point out to several methodological issues in our paper. First, the difference between the incidence of stroke and myocardial infarction (MI) in the 2 populations (wet age-related macular degeneration [AMD] using intravitreal bevacizumab and those not taking bevacizumab) is expected. As discussed in our paper, control patients who were not taking bevacizumab in the cohort analysis had a higher baseline cardiovascular risk profile than bevacizumab users, which naturally led to different incident rates for MI and stroke.
Source: American Journal of Ophthalmology - April 15, 2016 Category: Opthalmology Authors: Mahyar Etminan, David A. Maberley, David W. Babiuk, Bruce C. Carleton Tags: Correspondence Source Type: research

Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration
Purpose of review: The purpose of review is to summarize the literature addressing nonocular adverse events in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor (VEGF) inhibitors and to present possible mechanisms of effect. Recent findings: The incidence of overall nonocular serious adverse events varied from 0 to 39.3% and nonocular adverse events ranged from 0 to 86.9%. Few studies have reported a significant association between use of intravitreal anti-VEGF agents and overall incidence of adverse events, stroke, myocardial infarction, nonocular hemo...
Source: Current Opinion in Ophthalmology - April 8, 2016 Category: Opthalmology Tags: RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens Source Type: research

Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies
Conclusion Published data on IVTB in AMRD provide only a low level of evidence on its cardiovascular safety and do not support any finite conclusions.
Source: Drug Safety - March 7, 2016 Category: Drugs & Pharmacology Source Type: research

Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration.
CONCLUSION: In this small but prospective clinical study no increased risk for cardiovascular events during the upload phase of the VEGF inhibitors ranibizumab and bevacizumab could be detected when taking the age and pre-existing cardiovascular diseases into consideration. PMID: 26801323 [PubMed - as supplied by publisher]
Source: Der Ophthalmologe - January 22, 2016 Category: Opthalmology Authors: Fischer C, Schäfer K, Dschietzig T, Hoerauf H Tags: Ophthalmologe Source Type: research

Risk of Myocardial Infarction and Stroke with Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration
To examine the risk of myocardial infarction and stroke with single and repeated doses of intravitreal bevacizumab in wet age related macular degeneration (AMD).
Source: American Journal of Ophthalmology - December 14, 2015 Category: Opthalmology Authors: Mahyar Etminan, David A. Maberley, David W. Babiuk, Bruce C. Carleton Tags: Original Articles Source Type: research

Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs after Intravitreal Injection.
Abstract Subretinal neovascularization and pathologic ocular angiogenesis are common causes of progressive, irreversible impairment of central vision, and dramatically affect quality of life. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the quality of life for many patients with age-related macular degeneration, diabetic retinopathy, and other ocular diseases involving neovascularization and edema. In these pathologies, the inhibition of intraocular VEGF is the only therapy that can preserve vision. Four anti-VEGF drugs are currently used to treat ocular neovascularization; pegaptanib, ...
Source: Current Drug Metabolism - October 1, 2015 Category: Drugs & Pharmacology Authors: Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C Tags: Curr Drug Metab Source Type: research

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis
Conclusions The study revealed only a modest superiority of aflibercept 2 mg and ranibizumab 0.5 mg over other formulations and dosages.
Source: British Journal of Ophthalmology - January 20, 2015 Category: Opthalmology Authors: Schmid, M. K., Bachmann, L. M., Fas, L., Kessels, A. G., Job, O. M., Thiel, M. A. Tags: Retina, Neurology Review Source Type: research